An investigation on behalf of investors of Ionis Pharmaceuticals Inc shares over potential securities laws violations by Ionis Pharmaceuticals Inc and certain of its directors and officers was announced.
Investors who purchased shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Ionis Pharmaceuticals In, formerly Isis Pharmaceuticals, Inc., regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Ionis Pharmaceuticals Inc reported that its annual Total Revenue rose from $283.70 million in 2015 to $346.62 million in 2016 and that its Net Loss declined from $88.28 million in 2015 to $86.56 million in 2016.
On March 6, 2017, Ionis Pharmaceuticals Inc’s subsidiary Akcea Therapeutics revealed data from a Phase 3 study of volanesorsen, its experimental therapy for familial chylomicronemia syndrome. Akcea Therapeutics announced that 10 of the 66 patients that were involved in the study have discontinued treatment. Half of the patients who discontinued the therapy cited injection site reactions, and the other half discontinued due to platelet declines. Ionis Pharmaceuticals Inc reported 8 serious adverse events associated with volanesorsen. Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) declined on March 20, 2017 to as low as $38.91 per share.
Those who purchased NASDAQ:IONS shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego